Biotech VC Funds

Cambridge Angels, established in 2001, is a prominent UK business angel network based in Cambridge. The group comprises over 60 affluent investors who provide smart capital and mentorship to startups and scale-ups primarily in the UK, focusing on science, engineering, and healthcare technology sectors. They have invested over £150 million in more than 120 companies. Notable investments by Cambridge Angels include companies like Paragraf, Arecor, Eagle Genomics, Privitar, and Healx. The group supports these companies not just financially, with typical investments ranging from £150,000 to £1.5 million, but also through strategic guidance, leveraging their extensive experience as successful entrepreneurs. Cambridge Angels is known for their commitment to fostering innovation without charging founders to pitch, ensuring that the entrepreneurial focus remains on development and growth. This investor group also holds educational sessions for portfolio companies, covering critical topics such as exit strategies and leadership development.

Cambridge Innovation Capital (CIC) is a venture capital firm based in Cambridge, UK, specializing in investing in deeptech and life sciences startups. Established to leverage the rich innovation ecosystem around the University of Cambridge, CIC manages over £500 million across its funds, focusing on supporting early to growth-stage companies. The firm plays a strategic role in fostering innovation by backing ventures that emerge from the Cambridge cluster, including university spinouts and collaborations with research institutes like the Wellcome Sanger Institute. CIC's investment portfolio reflects its emphasis on groundbreaking technology, with companies like CMR Surgical, known for its Versius robotic surgery system, and PragmatIC Semiconductor, which focuses on flexible electronics. The firm also invests in biotech firms like Microbiotica, which leverages the microbiome for therapeutic purposes, and quantum computing ventures such as Riverlane. With its commitment to sustainability and a robust focus on ESG (Environmental, Social, and Governance), CIC aims to create long-term value while fostering responsible business practices. The firm not only provides capital but also strategic support, often co-investing alongside other prominent funds and facilitating connections through initiatives like DeepTech Labs and Start Codon, two accelerators designed to help startups navigate early commercial challenges. Led by Managing Partner Andrew Williamson, CIC remains deeply integrated within the Cambridge ecosystem, collaborating with universities, research hubs, and industry leaders to drive the next wave of technological breakthroughs​.

Camford Capital is a Palo Alto-based venture capital firm that focuses on investing in transformative technologies across sectors like enterprise software, consumer products, fintech, and healthcare. Founded in 2021, the firm partners with early-stage and growth-stage companies in the U.S. and Asia, seeking to back innovative solutions that have the potential to reshape industries globally. Camford has built a strong portfolio that includes notable investments such as CG Oncology and Totus Medicines, which highlight its emphasis on life sciences. Additionally, the firm has backed Viz.ai an AI-driven healthcare company, and Stori, a fintech unicorn offering credit card solutions in Latin America. The firm is particularly known for its ability to identify and support companies that leverage exponential technologies to tackle complex problems in healthcare and financial services. The leadership team at Camford consists of experienced entrepreneurs and investors, including Andrew Gu and Ali Farahanchi, who bring deep operational and investment expertise. Their strategy combines hands-on partnership with founders and an ability to co-invest with global players like General Catalyst and Khosla Ventures. Camford Capital tends to invest anywhere between $500,000 and $10 million, with a preference for leading funding rounds. Entrepreneurs seeking investment can reach out to the firm through its website for inquiries.

Canaan is a leading early-stage venture capital firm that focuses on transformative ideas in the technology and healthcare sectors. With a strong history spanning over 35 years, Canaan has invested in notable companies such as Instacart, LendingClub, The RealReal, and Match.com. The firm has managed to achieve impressive exits, including IPOs for companies like TheRealReal, Arvinas, and Day One Biopharmaceuticals. Canaan’s investment strategy covers a wide range of industries including enterprise software, consumer tech, fintech, and frontier tech. They are particularly noted for their deep involvement in healthcare, with significant investments in areas such as oncology, immunology, and neurology. Their portfolio includes companies like Dexcom, Synthekine, and Vivace Therapeutics, among others. The firm manages over $6.8 billion in assets and recently closed its thirteenth fund with $850 million to continue supporting innovative startups through their early and growth stages. This new capital will help expand their investments in robotics, AI/ML, cybersecurity, and genetically defined precision medicines​.

Candy Ventures is a private investment portfolio founded in 2014 by British entrepreneur Nick Candy, operating from Luxembourg under the name Candy Capital. The firm backs visionary founders with global ambitions, leveraging Candy's extensive network to accelerate businesses across fintech, deep tech, augmented reality, digital media, consumer, sports, biotech, and water infrastructure. With 21 companies in the portfolio, Candy Ventures has established itself as a distinctive early-stage vehicle for founders building across Europe and the United States. The firm primarily invests at the Seed stage, deploying checks of $500,000 to $10 million. The portfolio has produced three IPOs — including Lyft's listing on the Frankfurt Exchange at an $8.42 billion market cap in March 2019 and audioBoom on the London Stock Exchange — along with six acquisitions including BlockFi and Blippar, whose IP assets Candy acquired in January 2019. Cera, a homecare technology company, reached unicorn status in 2025. The most recent exit was VibePay in April 2025. Candy Ventures operates with a lean, high-conviction model — two team members making selective bets alongside a deep network of strategic relationships. The firm's edge lies in Nick Candy's access to capital markets, luxury real estate networks, and cross-sector relationships that can open doors for portfolio companies beyond what conventional venture capital provides. That distinctive founder-value proposition shapes every investment decision.

Cantos Ventures, established in 2016 and headquartered in San Francisco, focuses on pre-seed and seed-stage investments in frontier technologies. The firm invests in sectors such as climate tech, computational biology, aerospace, and advanced computing. Notable companies in their portfolio include Solugen, Astranis, and Public, reflecting their commitment to transformative technologies. Cantos Ventures emphasizes investing in high-potential startups tackling significant global challenges. Recent investments include Furno Materials, which raised $6.5 million for decarbonizing cement production, and Shinkei Systems, which secured $6.27 million to innovate in sustainable fish processing. The firm collaborates with co-investors like Y Combinator and 8VC, ensuring a robust support network for their portfolio companies. The team at Cantos Ventures, led by Ian Rountree and Natalie Estrella, leverages extensive experience to support founders. They adopt a hands-on approach, providing strategic guidance and access to global networks. Startups seeking investment should demonstrate strong technical capabilities and a clear vision for addressing large-scale problems. Cantos Ventures is recognized for its selective and impactful investment strategy, often leading rounds with substantial financial commitments to drive growth and innovation

Canvas Ventures is a Portola Valley-based venture capital firm founded in 2013 by Rebecca Lynn, Gary Little, and Paul Hsiao. Specializing in Series A and B investments, Canvas Ventures primarily focuses on fintech, digital health, AI, marketplaces, and logistics sectors. With a strategic emphasis on companies poised for significant growth, the firm offers more than just capital, providing extensive go-to-market expertise, sales strategy, and growth guidance to their portfolio companies. Notable investments include Luminar Technologies, which went public via SPAC in 2020, and successful ventures like Zola, Vida Health, and Transfix. Their recent fund, CV3, raised $350 million, bringing their total capital raised to $835 million. Canvas typically leads funding rounds with investments ranging from $5 million to $15 million. The firm is led by experienced partners, including Rebecca Lynn, a renowned investor with deep expertise in consumer credit and healthtech. Canvas Ventures has a mission-driven approach, deeply engaging with their portfolio companies to ensure their success. The team has also established the Canvas GTM Council, comprising top marketing and sales professionals who provide invaluable insights to portfolio companies. Canvas Ventures prefers to work with founders who are tackling transformative problems and are prepared for the long-term journey of building significant companies. They maintain a collaborative and supportive relationship with entrepreneurs, helping them navigate challenges and scale their businesses effectively.

CapHorn Invest is a Paris-based venture capital firm established in 2011, focusing on early to growth-stage investments in sectors such as climatetech, healthtech, and enterprise software. The firm typically invests between €1 million and €15 million, targeting startups that offer high-growth potential and innovative solutions across Europe. CapHorn is part of the Anaxago Group, aligning its investment strategy with the goal of driving sustainable innovation and impact. CapHorn supports startups with not just capital but also strategic guidance, leveraging its network of business leaders and experts to accelerate growth. The firm has backed notable companies such as Tilak Healthcare, Finalcad, and InterCloud, all of which align with its focus on transformative B2B solutions. The firm’s investment strategy is built around fostering companies that address critical societal challenges, such as sustainability and technological advancements in healthcare and digital infrastructure. CapHorn primarily focuses on Series A to Series C funding rounds, partnering with exceptional entrepreneurs to help them scale their businesses both in France and internationally. The leadership team at CapHorn includes experienced venture capitalists and industry experts, ensuring that startups receive hands-on support throughout their growth journey. With over €200 million in assets under management, CapHorn remains a key player in the European VC landscape, committed to driving innovation across its target sectors.

Capagro is a Paris-based venture capital firm established in 2014, focusing on investments in the AgTech and FoodTech sectors. The firm aims to accelerate innovation and development across the agricultural and food value chains, supporting companies that offer sustainable and impactful solutions. Capagro's portfolio includes notable companies such as Naïo Technologies, which develops agricultural robotics, Cuure, a personalized health and wellness provider, and NICK'S, a snack food manufacturer. Other significant investments are in La Belle Vie, an e-commerce grocery platform, and ecoRobotix, which specializes in precision farming robotics. The firm typically invests between €1 million and €5 million per round, emphasizing early-growth companies that already have significant revenues or are close to commercialization. Capagro has made 36 investments to date, with a strategy focusing on three main segments: upstream agricultural production, downstream consumer food products, and energy efficiency innovations in the agro-industrial sector. Capagro is led by Jean-Baptiste Cuisinier and Jérôme Samson, who bring extensive experience in food, agribusiness, and venture capital. Their deep industry knowledge and strategic support have made Capagro a valuable partner for innovative startups aiming to scale and make a global impact. The firm manages assets of approximately €124 million, backed by notable investors including Bpifrance and Groupe Avril. Capagro continues to seek new investment opportunities to bridge the funding gap in the European AgTech and FoodTech industries.

Capital Factory is a prominent venture capital firm and accelerator based in Austin, Texas, that serves as a major hub for entrepreneurs across Texas. Founded in 2009, it supports early-stage tech startups through investments, mentorship, and community access. Its program emphasizes long-term engagement, providing startups with free coworking space, extensive mentorship from industry leaders, and introductions to investors. Capital Factory stands out with its robust network, which includes hundreds of mentors and partnerships with major tech companies like Amazon and Google, offering hosting credits and other resources to its portfolio companies. Capital Factory’s accelerator is not your typical boot camp. Instead, startups can immerse themselves in the program, gaining the support needed to scale, with Capital Factory taking a 1% equity stake. The firm is particularly active in sectors like artificial intelligence, digital health, education technology, and SaaS, making investments in companies such as Zen Business and Aceable. Beyond its Austin headquarters, Capital Factory has expanded its influence with programs in Dallas, Houston, and San Antonio, making it a central player in the Texas startup ecosystem.

Capnamic Ventures, based in Cologne and Berlin, is a premier early-stage venture capital firm with a strong focus on technology startups in German-speaking countries. They support companies from Pre-Seed to Series A, specializing in the critical early decisions that shape a startup's trajectory. Their portfolio boasts notable investments like LeanIX, Adjust, and CrossEngage, with successful exits demonstrating their strategic acumen. Capnamic’s investment strategy emphasizes hands-on support, leveraging their extensive industry network and resources to help startups with everything from setting up financial departments to making executive hires. They pride themselves on being sparring partners to their founders, offering honest, empathetic advice and remaining steadfast supporters through all stages of growth. Led by Managing Partners Christian Siegele, Jörg Binnenbrücker, and Olaf Jacobi, Capnamic brings together a wealth of experience and a robust network of over 100 Limited Partners. Their focus on the German tech scene is complemented by selective international investments, ensuring a deep-rooted connection with local entrepreneurs while remaining open to global opportunities​.

Capricorn Partners, headquartered in Leuven, Belgium, is a leading independent manager of venture capital, growth capital, and quoted equity funds. The firm focuses on innovative companies that leverage technology as a competitive advantage, particularly in sectors such as digital technologies, health, and cleantech. Capricorn Partners manages several funds, including the Capricorn Cleantech Fund, Capricorn Digital Growth Fund, Capricorn Health-Tech Fund, and Capricorn Fusion Fund, which targets opportunities with a specific China strategy. They also manage Quest for Growth, integrating both quoted and private investments, focusing on European companies expected to produce higher than average growth in digital, health, and clean technologies. The firm has a strong commitment to ESG principles and aims to create both financial return and strategic value for its clients. Their investment philosophy is rooted in supporting innovative sectors that drive positive change, making them a pivotal player in the venture capital landscape. Capricorn’s team comprises experienced investment managers with deep technology expertise and broad industrial experience. They offer a unique mix of technology and investment expertise, creating an ecosystem that supports superior returns through the combination of investable capital, innovative ideas, capable entrepreneurship, and business management. For entrepreneurs, Capricorn Partners provides not only capital but also strategic guidance and support, leveraging their extensive network and industry knowledge to foster growth and innovation in their portfolio companies​.

The Carbon to Value (C2V) Initiative is a dynamic accelerator focused on advancing carbontech innovations—technologies that capture, convert, and store carbon dioxide (CO₂) into valuable products or services. Established in 2020, the initiative is a collaborative effort between Greentown Labs, the Urban Future Lab at NYU Tandon School of Engineering, and Fraunhofer USA. C2V's core mission is to build a thriving carbontech ecosystem that supports the commercialization of breakthrough technologies aimed at mitigating climate change. Since its inception, C2V has supported over 25 startups that have collectively raised more than $350 million in follow-on funding. The initiative connects entrepreneurs with corporate, nonprofit, and government leaders through its Carbontech Leadership Council (CLC), which includes prominent organizations like NYSERDA, Unilever, and Johnson Matthey. The C2V Initiative has attracted a wide array of promising startups, including companies like Capro-X and Carbon to Stone, which are pioneering new methods to address CO₂ emissions. These startups benefit from tailored mentorship, strategic business connections, and opportunities for technology validation, all designed to accelerate their path to market. The initiative is part of a broader movement to establish a new carbontech economy, one that turns carbon from a waste product into a resource, driving both environmental and economic value.

Carbon13 is a venture builder focused on addressing the climate emergency by helping founders create scalable startups that contribute significantly to reducing carbon emissions. Based in Cambridge and Berlin, Carbon13’s programs support entrepreneurs from the earliest stages of ideation through to pre-seed investment. Their goal is for each venture to eventually reduce 10 million tonnes of CO2e annually once scaled. The organization has launched over 70 climatetech ventures since 2021, including notable startups like Kita, which offers the world’s first carbon removal insurance, and Materials Nexus, which uses AI and quantum mechanics to design low-carbon materials​. Carbon13's venture builder program focuses on both technical and commercial founders, fostering collaborations between scientists, engineers, and entrepreneurs to build impactful solutions. Participants gain access to a vast network of domain experts and investors, including partnerships with organizations like Barclays and EY. The program emphasizes a dual focus on achieving commercial success and measurable carbon reduction. The fund actively invests through its SEIS Funds, targeting ventures that align with its mission of achieving net-zero emissions by 2050.

Carduso Capital is a Groningen-based venture capital firm focused on supporting innovative technology companies, particularly those linked to the University of Groningen and the University Medical Center Groningen. The fund targets sectors such as life sciences, energy, and sustainability, with a special interest in spin-offs and startups leveraging university research. Carduso Capital’s investments range from €100,000 to €5 million, covering companies at various stages of growth, from seed to expansion phases. In addition to financial backing, Carduso takes an active role in providing strategic and managerial support to its portfolio companies, ensuring they have the resources and guidance needed to thrive. Their investment strategy emphasizes long-term collaboration and supports multiple financing rounds if necessary. The fund looks for businesses with completed proof-of-concept and functional prototypes that are nearing market readiness. Portfolio companies must address unmet needs with clear, realistic market-entry strategies. Some notable investments include Ivy Medical, Qdi Systems, and ViroTact, reflecting their focus on high-potential technologies within their core sectors. Led by fund managers Koos Koops, Robert Polano, and Frits Kok, Carduso Capital combines deep industry knowledge with a strong network, enabling startups to benefit from both financial and operational expertise. The team prioritizes fostering long-term success, even during challenging periods, and is deeply involved in ensuring the sustainable growth of its companies. Their active engagement and sector-specific focus make them a valuable partner for tech-driven startups seeking strategic and financial support.

Carnrite Ventures is the venture capital arm of the Carnrite Group, founded in 2015 and headquartered in Houston, Texas. With approximately $25 million in assets under management, the firm partners with entrepreneurs building transformative companies in energy, climate technology, and healthcare technology. The firm was built by operators: Founder and Managing Partner Alan Carnrite leads alongside Jeffrey Carnrite, who joined in 2020 and oversees deal sourcing, due diligence, and portfolio management. Carnrite leads rounds from Pre-seed through Series B, deploying checks of $100,000 to $2 million across 65 investments in energy, cleantech, healthtech, and biotech. The portfolio has produced 17 exits over the firm's decade of investing. Notable portfolio companies include Haven in energy storage, Wheeler Bio in biotechnology, and Nest Collaborative, a healthcare and lactation services platform that raised a Series A in January 2024. The most recent investment was in RBL LLC, a biotech venture creation studio, in September 2025. Beyond capital, Carnrite provides executive leadership, turnaround services, and back-office operational support to portfolio companies — reflecting roots as an operator-first organization rather than a conventional financial investor. Situated at the heart of Houston's energy ecosystem, the firm maintains strong ties to the traditional and emerging energy sector, giving portfolio companies direct access to an industry network that spans major operators, corporates, and technical experts across the Texas energy corridor.

Casdin Capital, established in 2012 by Eli Casdin, is a New York-based venture capital firm with a focus on life sciences and healthcare. The firm specializes in investing in companies that are at the forefront of scientific and technological advancements in areas such as molecular medicine, biotechnology, genomics, and synthetic biology. Notable investments by Casdin Capital include high-impact companies like 23andMe, Adaptive Biotechnologies, Recursion Pharmaceuticals, and Ginkgo Bioworks. These investments highlight the firm’s commitment to transformative technologies in health care, gene editing, and diagnostic platforms. Casdin Capital's strategy revolves around funding companies that leverage data and precision-based therapies to revolutionize the healthcare industry. They focus on early-stage to late-stage investments, providing substantial financial support to help these companies scale and achieve significant milestones. The firm has managed to build a robust portfolio with 250 investments and 87 exits, demonstrating a strong track record of successful investments and strategic exits. Key team members include Eli Casdin as the Founder and Chief Investment Officer, Alexandria Fisk as Chief Operating Officer, and Lawrence Canzoneri as Chief Financial Officer. The team’s expertise and deep industry knowledge enable them to identify and support innovative startups effectively. Casdin Capital's approach combines strategic investments with deep sector expertise, positioning them as a leading player in the life sciences investment landscape, actively supporting companies that are poised to make groundbreaking advancements in health and biotechnology.

AVG Funds, also known as Alumni Ventures Group, is a prominent venture capital firm that leverages the power of alumni networks to invest in innovative startups across various sectors. Founded with the mission to democratize venture capital, AVG Funds has become one of the most active venture firms globally. They manage over $200 million in assets and have made more than 115 investments in the past year alone. AVG Funds focuses on diverse industries, including AI and machine learning, health tech, fintech, cleantech, and cybersecurity. Notable investments include companies like Adventr, a media and information services platform, and Eclypsium, which specializes in cybersecurity for enterprise hardware. Their portfolio also features startups like PartySlate, a digital platform for event planning, and Venus Aerospace, a company developing high-speed transport technologies. The firm operates through a network of alumni funds associated with top universities such as Harvard, MIT, Stanford, and Yale. This structure enables AVG to tap into a vast network of alumni entrepreneurs and investors, providing a rich source of deal flow and support for portfolio companies. AVG Funds typically invests in early to growth-stage companies, with check sizes ranging from $100,000 to $2 million. They emphasize a hands-on approach, providing not only capital but also strategic guidance and connections to help startups scale and succeed.

Catalio Capital Management is a multi-strategy investment firm focused on breakthrough biomedical technology and innovative healthcare companies. Founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein, Catalio specializes in private equity, private credit, and public equities strategies, supporting companies from inception through to IPO or acquisition. The firm’s portfolio includes notable companies such as Affini-T, which is developing precision T-cell therapeutics for solid tumors, and Boost Neuroscience, focusing on therapies to combat cognitive aging and neurodegeneration. Catalio has also invested in companies like Octant, Inc., and Pheast Therapeutics, demonstrating a strong commitment to advancing precision medicines and novel cancer therapies. Catalio's strategy involves close collaboration with their portfolio companies, leveraging a network of over 36 world-renowned scientists to identify and invest in cutting-edge biomedical technologies. This approach has led to successful investments in companies like Thrive Earlier Detection, which was acquired by EXACT Sciences for $2.15 billion, and Personal Genome Diagnostics, acquired by LabCorp for $500 million.

Catalyst Health Ventures (CHV) is a Boston-based venture capital firm founded in 2000, exclusively focused on innovative early-stage MedTech companies. With over two decades dedicated to the healthcare sector, the firm invests in visionary teams developing breakthrough medical technologies that address significant global unmet clinical needs. The team comprises 13 members including three partners and one venture partner, operating from its office at 129 South Street in Boston. CHV leads rounds at the Seed and Series A stages, writing checks of $1 million to $5 million with continued participation in follow-on rounds through exit. Across 80 investments, the firm has recorded 12 portfolio exits — including acquisitions by Boston Scientific, Veracyte, Agilent Technologies, Life Technologies, and W.L. Gore & Associates, as well as Sera Prognostics' NASDAQ IPO. Key focus areas include oncology, cardiovascular disease, obesity, and women's health, spanning therapeutic devices, diagnostics, drug delivery, and digital health. Recent investments include Conformal Medical, Esperto Medical, Venova Medical, and Aria CV. CHV brings strategic insight, deep industry expertise, and a hands-on collaborative approach to every portfolio relationship. The firm's particular strength lies in helping founders navigate the distinctive regulatory and commercialization complexities of the medical device and diagnostics landscape — a path that requires far more than capital. That specialization, sustained consistently over 25 years, has made Catalyst Health Ventures one of the most experienced dedicated MedTech investors in the United States.

Catapult Ventures is one of the most experienced venture capital fund managers in the United Kingdom, founded in 1999 and headquartered in Leicester in the Midlands. The firm has successfully managed numerous discrete venture capital funds totaling approximately £130 million on behalf of public and private sector investors, completing 151 investments across its history. Key funds include the £30 million East Midlands Regional VC Fund, the £20 million West Midlands seed fund, the £30 million Catapult Growth Fund (an Enterprise Capital Fund), and the £31 million GM&C Life Sciences Fund for Greater Manchester and Cheshire. Catapult leads rounds at the Seed through Series B stages, deploying checks of £50,000 to £2 million across healthcare, life sciences, pharmaceuticals, software, and advanced manufacturing. The firm's exit track record demonstrates consistently strong multiples: R2C Online at 12.6x, Accutronics at 9.1x, Yospace at 6.9x, Oxford Cryosystems at 5.2x, Lumora at 4.7x, and Monica Healthcare at 3.6x. Other notable exits include Abzena, Left Hand Robotics, and Ergomed. The most recent investment was Array Labs at Series A in January 2026. Catapult Ventures combined operations with Opus Ventures in 2013, deepening its regional footprint and talent base. The firm's multi-decade presence in the UK Midlands — a region often underserved by London-centric capital — reflects a deliberate focus on building enduring companies from inception through exit across the full life sciences and technology innovation cycle.

Cathay Capital is a global investment firm known for its cross-border investment strategies, supporting companies across various stages from venture to growth. Founded in 2007, the firm has established a strong global presence with offices in major cities such as Paris, New York, Shanghai, and San Francisco. With over $4.5 billion in assets under management, Cathay Capital invests across sectors including healthcare, consumer goods, digital technology, and energy, aiming to foster sustainable transformation and globalization. The firm operates through several specialized funds, such as Cathay Innovation, Cathay Health, and regional initiatives like the Seaya Cathay Latam Fund. Cathay Innovation focuses on digital transformation, investing in companies at the forefront of the tech revolution, with a portfolio that includes firms like Chime, KaiOS, and Ledger. Meanwhile, Cathay Health, a €500 million fund, targets companies at the convergence of healthcare, life sciences, and technology, helping ventures scale globally with investments in firms like Tissium and Kojin Therapeutics. Cathay Capital's strategy emphasizes connecting startups with established corporations to drive innovation and expansion, leveraging its extensive network across Europe, North America, and Asia. The firm has also launched partnerships to enhance its reach, such as the collaboration with Seaya Ventures to support Latin American startups, reflecting its commitment to fostering diverse and sustainable growth globally.

Cathay Innovation, founded in 2015, is a global venture capital firm affiliated with Cathay Capital. The firm focuses on multi-stage investments in innovative startups across various sectors, including AI, fintech, digital health, consumer tech, and energy. With a presence in North America, Europe, Asia, and Latin America, Cathay Innovation leverages its global network to support entrepreneurs in scaling their businesses. Notable investments in Cathay Innovation's portfolio include Ledger, a leading provider of blockchain-based hardware wallets for cryptocurrency, and Glovo, a Spanish on-demand delivery service that was acquired by Delivery Hero. Other significant investments are Owkin, which uses AI for drug discovery and precision medicine, and Kredivo, a fintech company providing consumer loans in Indonesia. The firm has also seen several successful exits, such as the IPO of Wallbox, a smart charging company listed on the New York Stock Exchange, and the acquisition of Getaround, a peer-to-peer car sharing service. Cathay Innovation has a strong track record of identifying and nurturing high-growth companies, with multiple portfolio companies achieving unicorn status. Led by a diverse team of 45 members, including 17 partners, Cathay Innovation emphasizes a collaborative approach, providing strategic support and leveraging its extensive ecosystem to help startups thrive globally. The firm continues to drive innovation and positive impact through its investments in technology-driven companies.

Cathexis Ventures is a venture capital firm based in Houston, Texas, and serves as the venture arm of Cathexis Holdings. Established in 2018, Cathexis Ventures has a diverse investment portfolio with over 100 companies. They primarily focus on seed-stage investments but also participate in pre-seed and Series A rounds. Their investment strategy includes an 80% focus on seed, 10% on pre-seed, and 10% on Series A investments, with initial check sizes ranging from $250,000 to $1,000,000, and up to eight-figure follow-on investments. The firm invests across various sectors, including SaaS (60%), hardware (30%), and consumer (10%) products, with a geographic focus of 70% in North America and 30% internationally. Notable investments include companies like Betterhalf, an AI-enabled matchmaking platform, and BlueCargo, which focuses on smarter container movement. Other significant investments span industries such as healthcare compliance (Verifiable), construction operations (Tenderd), and carbon capture technology (Heimdal). Cathexis Ventures is led by a team of experienced investors and professionals who aim to support extraordinary founders building innovative products with speed and efficiency.

Cavallo Ventures is the corporate venture capital arm of Wilbur-Ellis Holdings, a privately owned family business founded in 1921. Established in 2017 and headquartered in San Francisco, the firm has invested more than $60 million in approximately 42 startups focused on agritech, food technology, and sustainability. President and CEO Mike Wilbur, a founding member with over 20 years at Wilbur-Ellis, leads the effort alongside Managing Director Brett Morris, who joined in January 2021 with nearly a decade of agritech venture capital and corporate development experience. Cavallo leads rounds at the Seed through Series B stages, deploying checks of $1 million to $5 million. The portfolio spans agronomy, sustainable agriculture, animal and human nutrition, and agri-software. Notable companies include Sound Agriculture, Agtonomy (autonomous tractors), FarmWise (acquired by Taylor Farms in April 2025), Taranis in crop intelligence, Beta Hatch in insect protein, Crop Enhancement, Boost Biomes, and Performance Livestock Analytics. The firm has recorded three exits, with FarmWise being the most recent. Cavallo's investment focus aligns directly with Wilbur-Ellis's four business divisions — agronomy, aquafeed, cosmetics ingredients, and nutrition — giving portfolio companies access to deep industry relationships, market expertise, and distribution channels that financial investors cannot replicate. Beyond capital, Cavallo provides board seats and active support in strategy, executive recruiting, and fundraising, positioning the firm as an operational partner with real commercial skin in the game.

CDP Venture Capital is a leading venture capital firm based in Italy, launched with the goal of accelerating the country's innovation ecosystem. It operates as part of the National Innovation Fund (Fondo Nazionale Innovazione), with the primary aim of fostering the growth of startups across various sectors, including deep tech, medtech, biotech, digital, and more. The firm is driven by the mission to shape Italy's future by investing in high-potential businesses that are transforming strategic industries. CDP manages over €1 billion in assets and works to make venture capital a key pillar of Italy's economic development. The firm invests at various stages, from pre-seed and seed funding to Series A and beyond, with typical investments ranging between €1.5 million and €3 million. Their portfolio includes promising startups such as Empatica, GreenBone, and Mindesk, and they collaborate with national agencies and international partners to support Italy's entrepreneurial growth. A key initiative of CDP Venture Capital is its focus on technology transfer, helping bridge the gap between academic research and commercial success. The firm also actively promotes innovation in areas like AI, web 3.0, and cybersecurity, and it plays a critical role in positioning Italy as a hub for high-tech startups.

CDTI (Centro para el Desarrollo Tecnológico Industrial) is a Spanish public business entity under the Ministry of Science and Innovation. It supports technological development and innovation within Spain, mainly by channeling financial and technical assistance to companies working on R&D&I projects. One of its key initiatives, Innvierte, is a venture capital program designed to foster investment in innovative, high-tech startups. Through Innvierte, CDTI co-invests with private capital in technology-based enterprises, targeting sectors like biotech, fintech, artificial intelligence, and digital media. The program has committed over €450 million to co-investment projects and venture capital funds, positioning itself as a critical player in Spain’s innovation ecosystem. CDTI has been involved in significant rounds of funding for companies like Atani, Bdeo, and Odilo. CDTI’s investment approach focuses on supporting early-stage companies with disruptive potential, aiming to bridge the gap between innovation and commercialization. This public-private partnership strategy helps drive Spain’s technology transfer and entrepreneurial growth, supporting industries crucial to the country's economic future.

Centre Street Partners, founded in 2015 and based in New York, focuses on early-stage investments in the technology sector. Their investment strategy targets companies that develop frontier technologies for a rapidly evolving world. Notable investments include Drunk Elephant, Briogeo Hair Care, and Parade, all of which have seen successful exits. The firm invests primarily in the information technology sector, with a diverse portfolio that includes companies like OffDeal, Scream Truck, and Arcee.ai. Centre Street Partners typically invests in seed and early-stage rounds, supporting companies with innovative and scalable solutions. The team is led by General Partners Abie Cohen and Jonathan Kerstein, who bring significant expertise and experience to the firm. Centre Street Partners is committed to partnering with ambitious founders and providing the necessary resources to help their portfolio companies grow and succeed.

CentreStone Ventures is a life sciences-focused private venture capital fund founded in 2004 and based in Winnipeg, Manitoba, Canada — geographically at the center of North America. The firm invests in companies developing early-stage therapeutics, medical devices, diagnostics, and novel drug delivery methods, targeting opportunities with clear unmet clinical needs, solid intellectual property foundations, and the potential to achieve market leadership. CentreStone deploys checks of $500,000 to $3 million at the Seed and Series A stages. Across seven portfolio investments, the firm has achieved three IPOs and one acquisition — a strong exit rate relative to portfolio size that reflects a selective, high-conviction approach to company selection. The small team of three manages a focused book of life sciences companies, prioritizing depth of engagement over breadth of portfolio. The firm appears to be in portfolio management mode rather than actively making new investments, with the most recent investment recorded in 2018. During its active period, CentreStone played a niche institutional role in Canada's healthcare and biotech ecosystem — channeling specialized venture capital into a region that generates significant life sciences research through its university and medical community but has historically had limited access to dedicated early-stage health technology investment capital.

Cercano Management is a venture capital firm spun out from Vulcan Capital, originally established by Microsoft co-founder Paul Allen. Based in Bellevue, Washington, with a new office in Atlanta, the firm focuses on early-stage investments across sectors like technology, consumer, life sciences, and data intelligence. With a patient and methodical approach, Cercano has over two decades of investment experience, boasting a diverse portfolio of more than 120 companies. The firm is particularly active in both the West Coast and Southeast U.S., with an increasing presence in Atlanta to capitalize on early-stage opportunities in emerging markets. Key investments include Group14 Technologies, AdaptX, and Twelve, demonstrating their strong interest in transformative technologies and sustainability ventures. Cercano’s strategy revolves around long-term partnerships, often leading early rounds but maintaining flexibility to support companies through later stages. Their average check size varies, but they are known to lead or co-lead rounds, particularly in seed and Series A investments. Startups looking to engage with Cercano should prioritize demonstrating innovative solutions and a strong growth trajectory. The team, led by CEO Christopher Orndorff and supported by leaders like Daley Ervin in Atlanta and Tommy Teo in Singapore, offers global insights with a deep expertise in scaling tech companies.

CerraCap Ventures, based in Costa Mesa, California, is a global venture capital firm focused on early-stage B2B technology companies. Their key sectors are health tech, enterprise AI, and cybersecurity. Using their unique Sales & Scale™ model, they guide startups through an industrialized process designed to accelerate sales, scale product development, and facilitate successful exits. CerraCap leverages an extensive network of Fortune 500 CXOs to secure early proofs of concept and streamline product adoption. Their investment strategy is geared toward companies that solve real-world problems in healthcare and digital security, with a focus on chronic disease management and securing digital environments. Some notable portfolio companies include Deep Instinct and Dathena, specializing in cybersecurity through AI-driven solutions. CerraCap often leads rounds and provides hands-on support to help startups achieve growth, reduce sales cycles, and gain traction with key customers. The team, led by co-founders Saurabh Ranjan and Saurabh Suri, draws on years of industry expertise to mentor and position companies for success in global markets​.

FinTech Venture Capital is dedicated to investing in innovative financial technology companies at various stages of growth. Their investment strategy spans pre-seed, seed, Series A, and Series B rounds, with a focus on supporting startups that offer disruptive solutions in the fintech space. Notable investments by FinTech VC include high-profile companies such as Stripe, a leader in online payment processing, and Affirm, a prominent player in the buy-now-pay-later market. Other significant investments include SoFi, a personal finance company that offers student loan refinancing, mortgages, and personal loans, and Nubank, a digital bank based in Brazil that has revolutionized banking in Latin America. FinTech VC's portfolio reflects a strong commitment to fostering growth in companies that leverage technology to improve financial services and infrastructure. They provide not only capital but also strategic support and industry expertise to help their portfolio companies scale effectively and achieve significant market impact.

Change Ventures, founded in 2016 and headquartered in Tallinn, Estonia, is a leading venture capital firm focused on early-stage investments in the Baltic region. The firm has built a strong portfolio with notable investments in companies such as Formaloo, a software development applications firm, and RivalSense, a business productivity software company. They emphasize supporting ambitious Baltic founders across various sectors including aerospace, defense, and hospitality. Change Ventures has made 59 investments to date, demonstrating their commitment to nurturing innovative startups. They have seen successful exits, including Nordigen, a company acquired in 2022. The firm's investment strategy is centered around providing not only capital but also mentorship and strategic guidance to help startups scale effectively. The team at Change Ventures includes experienced professionals like Andris Berzins, who has held C-level roles in successful startups and co-founded TechHub Riga and TechChill. Other key members include Yrjö Ojasaar, a seasoned tech-startup CEO and angel investor, and Rait Ojasaar, an experienced tech entrepreneur and mentor. This diverse team brings a wealth of expertise and a deep understanding of the startup ecosystem in the Baltic region. By leveraging their extensive network and deep industry knowledge, Change Ventures continues to play a pivotal role in the growth and success of early-stage startups in the Baltics​.

Charge Ventures, founded in 2015 and based in New York City, is a venture capital firm that focuses on early-stage investments. The firm typically invests in startups operating in sectors like business productivity software, multimedia and design software, social and platform software, and healthcare. Charge Ventures has a diverse portfolio that includes companies such as Transfix, a marketplace for on-demand load matching and freight booking services; Livepeer, a decentralized live video streaming platform; and Electric, an IT management software company that achieved unicorn status. Other notable investments include Parsley Health, a data-driven medical practice offering personalized healthcare, and GRIN, a platform for influencer marketing solutions. The firm has made 86 investments and achieved 15 exits, including Bulletin, SimpleHealth, and Podz. Charge Ventures is led by co-founders and general partners Brett Martin and Chris Habachy, who bring extensive experience and a strategic approach to supporting their portfolio companies' growth and success.

Chartline Capital Partners, based in Wilmington, Delaware, is a venture capital firm focused on B2B technology companies. Founded in 2012 by Benjamin duPont and Phillip Stern, Chartline invests in enterprise and industrial technology companies that improve efficiency, reliability, and safety across core industries. The firm specializes in scaling companies that have already achieved a strong go-to-market strategy, with annual revenues of $3-5 million. Chartline typically invests between $500K and $5 million, supporting its portfolio companies with strategic introductions and customer connections to accelerate growth. Chartline focuses on sectors such as HR Tech, Financial Technology, Property Technology, and Digital Industrials, providing capital and expertise to companies looking to scale in these areas. Notable investments include PowerToFly, Gig Wage, and Humi, all of which are involved in business productivity and financial services. Chartline's investment approach emphasizes strategic focus, operational cadence, and strong governance to help companies thrive and scale effectively. Led by experienced entrepreneurs and investors, including co-founder Ben duPont, Chartline is known for its commitment to improving corporate governance and maintaining high standards of fiduciary responsibility. The firm seeks to foster strong partnerships with founders and management teams, helping them navigate growth and operational challenges while ensuring long-term success.

Checkmate Capital is a venture capital and strategic advisory firm based in Pasadena, California, with a global reach, including a presence in Seoul, South Korea. Founded in 2017, Checkmate Capital focuses on investments in biotechnology, agriculture and waste technology, energy technology, and diversified technologies. The firm is deeply involved in the sectors it invests in, offering both financial backing and strategic advisory services to help companies grow and succeed. Checkmate Capital's portfolio spans a wide range of industries, including high-tech areas like biotechnology, where they invest in companies developing innovative health solutions, and energy technology, focusing on environmentally friendly and efficient energy solutions. The firm prides itself on its disciplined approach to investment, working closely with companies to create synergies that enhance value across its portfolio. In addition to its investment activities, Checkmate Capital also provides commercial and transaction advisory services, facilitating international licensing opportunities and partnerships that help its portfolio companies expand globally.

Cherry Ventures, founded in 2012, is an early-stage venture capital firm based in Berlin, with additional offices in London and Stockholm. The firm primarily invests in pre-seed and seed-stage startups across various sectors, including fintech, climate tech, consumer products, health tech, mobility, and SaaS. Cherry Ventures is led by partners Filip Dames, Christian Meermann, and Sophia Bendz, all of whom have extensive entrepreneurial experience from building companies like Zalando and Spotify. The firm recently launched its fourth fund at €300 million, focusing on disruptive technologies including crypto and web3. Notable portfolio companies include Infarm, AUTO1 Group, FlixBus, TWAICE, and Cazoo.

CincyTech is a venture capital firm based in Cincinnati, Ohio, focusing on seed-stage investments to drive economic growth and innovation in the Midwest. Founded in 2006, CincyTech has invested in over 140 companies, particularly in the healthcare, technology, and life sciences sectors. Some of their notable investments include Enable Injections, which raised $215 million in Series C funding for their wearable drug delivery devices, and Genetesis, a company that secured $17.5 million to advance their Cardioflux diagnostic imaging platform. Other prominent portfolio companies include ReadySet Surgical, Standard Bariatrics, and NaviStone, which leverage innovative solutions in their respective fields. In 2022, CincyTech reported a record $391 million in co-investments in its portfolio companies, reflecting its significant impact on the regional economy. The firm continues to focus on partnering with visionary founders to transform ideas into world-class companies, supporting them with strategic guidance and access to a robust network of co-investors.

Circular Innovation Fund (CIF) is a dynamic global growth-stage venture capital fund dedicated to advancing circular innovation. Co-managed by Cycle Capital and Demeter, CIF focuses on climate change mitigation and the circular use of resources, targeting sectors like new materials, eco-efficient processes, waste innovation, circular packaging, and logistics. CIF has a diverse portfolio with notable investments in companies such as Lizee, Evoco, Watttron, Vartega, and Novobiom, reflecting its commitment to sustainable business models. Operating globally, CIF invests across North America, Europe, and Asia, supporting growth-stage companies that offer breakthrough technologies to solve complex supply chain issues and reduce environmental impact. The fund’s strategy involves a thorough selection process, investing significant capital to scale innovations that can redefine industry standards. Typical investments range significantly, reflecting the tailored approach CIF takes with each portfolio company. Led by a seasoned team including partners Benoit Forcier, Mathieu Goudot, and principals Maya Hassa and Marius Thebault, CIF's expertise is bolstered by the extensive backgrounds of Cycle Capital and Demeter's leadership. With offices in Montreal, Paris, and a presence in key global markets, CIF actively supports its portfolio companies through a combination of capital and strategic guidance, emphasizing the fund's proactive engagement in fostering sustainable innovation.

Circulate Capital is a leading investment management firm focused on the circular economy, particularly in high-growth markets across South and Southeast Asia. Established to address the global plastic waste crisis, the firm invests in companies that are transforming waste management and recycling supply chains. Their flagship fund, the Circulate Capital Ocean Fund (CCOF), launched with backing from major global corporations such as PepsiCo, Unilever, and Coca-Cola, targets innovations that reduce plastic waste and promote sustainability. Circulate Capital operates through two main strategies: Circulate Capital Recycling Supply Chains, which scales effective recycling and waste management solutions, and Circulate Capital Disrupt, which focuses on disruptive innovations like reusable materials and alternative delivery models. The firm’s investments have supported companies like India’s Recykal and Indonesia’s Tridi Oasis, helping them grow from local startups into significant players in their respective markets. Additionally, Circulate Capital is committed to gender-smart investing, aiming to empower women across the waste management and recycling value chains. Their approach has been recognized by the 2X Challenge, highlighting their efforts to promote gender equality while driving impactful environmental change. With these initiatives, Circulate Capital not only aims to generate competitive financial returns but also to create positive environmental and social impact, setting new standards for sustainability-focused investments.

Cisco Investments, the corporate venture capital arm of Cisco, focuses on strategic investments in next-generation enterprise technologies. With over $2 billion in assets under management, Cisco Investments has a robust portfolio that includes companies specializing in AI/ML, cloud computing, cybersecurity, and IoT. Their investment strategy extends beyond financial backing, offering startups access to Cisco's vast network of experts, sales and marketing support, and a global customer base. One of their key initiatives is the Aspire Fund, a $50 million venture fund launched in 2020 to support diverse-led startups and venture funds. This fund specifically targets companies led by women and people of color, aiming to close the significant funding gap for these groups. Cisco Investments also partners with other venture funds such as Work-Bench and Acrew Capital to further their commitment to diversity and inclusion in the tech industry. The leadership team, including Janey Hoe, Derek Idemoto, and Prasad Parthasarathi, emphasizes a strategic approach to investment, integrating Cisco's innovation goals with their commitment to social justice and inclusion. This approach not only helps startups scale but also fosters a more inclusive tech ecosystem globally. Cisco Investments continues to be a driving force in the venture capital landscape, leveraging its strategic position and resources to support the growth and success of innovative startups across various technology sectors.

Civilization Ventures is a venture capital firm founded in 2017 with a strong focus on health tech and biology innovations. Based in Silicon Valley, the firm has grown from a $1M pilot seed fund to managing over $100M in capital. They have invested in over 60 companies across genomics, diagnostics, digital health, and synthetic biology, emphasizing preventative, personalized, and regenerative healthcare solutions. Notable investments include Rocket Pharma, which focuses on gene therapies for rare diseases, and Singular Bio, acquired by Invitae to enhance genetic screening in early pregnancy. Other significant exits include Lemonaid Health, acquired by 23andMe, and Rewrite, a gene editing company acquired by Intellia. The team at Civilization Ventures is composed of experienced biopharma executives and operators who have founded and sold companies. They support founders through a vast network and their extensive experience in the field. Additionally, they offer a unique fellowship program to train PhDs to become future entrepreneurs in the life sciences sector.

Claris Ventures is an Italian venture capital firm established in 2019, focusing on early-stage investments in high-potential biopharma companies. The firm's first fund, Claris Biotech I, targets innovations that are poised to enter clinical trials within 12 to 24 months. Claris Ventures is particularly interested in therapeutic areas such as oncology, immunology, and rare diseases—sectors that often have significant unmet medical needs. The firm's strategy involves not only providing capital but also offering hands-on support in areas like project management, finance, and strategic development, allowing scientific founders to focus on their research and development. Claris Ventures aims to build value around strong scientific evidence, with a mission to make a substantial impact on patient care. Claris Ventures leverages Italy's robust R&D ecosystem, drawing from local research centers, clinical institutions, and international collaborations. The team, led by Managing Partners Pietro Puglisi and Ciro Spedaliere, includes experienced professionals who are committed to guiding portfolio companies through the critical early stages of development. Some notable companies in their portfolio include NeoPhore, Resalis Therapeutics, and Kither Biotech, which are all working on breakthrough therapies in their respective fields.

Clave Capital is a prominent venture capital firm based in Pamplona, Spain, with a strong focus on the healthcare sector. Notable for their recent €50 million Clave Innohealth fund, they target high-growth potential startups across Europe, specifically in medtech, digital health, health-nutrition, and biotech sectors. Clave Capital’s portfolio includes promising startups like Innitius, which focuses on improving diagnostics for women’s health. Clave Capital primarily invests in early-stage to Series A funding rounds, with initial contributions ranging from €500k to €1 million, and potential follow-on investments up to €3 million per project. Their geographic focus extends throughout Spain and Europe. The firm’s investment strategy emphasizes not only financial backing but also active involvement in the growth and development of their portfolio companies. They maintain close relationships with research centers and hospitals, providing valuable expertise and connections to foster innovation. Clave Capital's experienced team, led by Chairman and CEO José Javier Armendariz and Director of Funds Santiago Lozano, has a track record of over 20 years and 90 investments, which positions them as a significant player in the European healthcare investment landscape. For startups looking to engage with Clave Capital, it’s advisable to highlight innovative potential and market leadership capabilities in the healthcare domain. Their preference for hands-on involvement means that demonstrating a collaborative approach could be beneficial.

Clay Capital, formerly known as VisVires New Protein, is a Singapore-based venture capital firm focused on agrifood technology. In 2023, the firm closed its second fund at $145 million, signaling a strong commitment to transforming the food and agriculture sectors. Clay Capital backs innovative startups across Europe, Asia, and Israel that are working to create sustainable and regenerative food systems. Its investment strategy targets technologies that address key issues like food security, sustainability, and environmental health. With initial investments ranging from $3 million to $8 million, Clay Capital supports startups working on solutions in areas such as regenerative agriculture, crop disease resistance, and sustainable packaging. The firm’s portfolio includes companies like Toopi Organics, which repurposes human urine as a bio-stimulant, and In Ovo, which develops sex determination technologies to reduce the culling of male chicks in the poultry industry. Clay Capital’s approach emphasizes connecting the Asian and European markets, leveraging its expertise and network to help startups expand globally. This cross-continental strategy reflects the firm’s vision of creating a healthier and more sustainable food system while fostering innovation in agrifood tech.

Clean Energy Ventures (CEV) is a venture capital firm focused on early-stage investments in climate technologies that can significantly reduce greenhouse gas emissions. Founded by experienced climate tech investors and entrepreneurs, CEV aims to commercialize disruptive technologies and innovative business models to address global climate challenges. Based in Boston, Massachusetts, and with a new office in London, CEV targets investments in sectors such as renewable energy, energy storage, carbon capture, and sustainable transportation. They prioritize technologies capable of mitigating at least 2.5 gigatons of CO2 emissions by 2050. Their investment strategy involves deep technical due diligence and hands-on support for portfolio companies, including leadership coaching, strategic marketing, IP development, and active board participation. CEV has a robust portfolio featuring companies like Noon Energy, which focuses on long-duration energy storage, and OXCCU, a developer of sustainable aviation fuel. The firm recently closed its second fund with $305 million, aiming to expand its impact and support more groundbreaking climate tech startups. The team at CEV includes notable figures like Nora Mead Brownell, a former FERC Commissioner, and Co-Founders Temple Fennell and Daniel Goldman, who bring extensive experience in energy and finance. Their combined expertise and strategic partnerships position CEV as a leader in the climate tech investment space.

Clean Growth Fund (CGF) is a pioneering £101 million venture capital fund launched in 2020, dedicated to supporting early-stage clean technology companies in the UK. Backed by cornerstone investors such as CCLA and the UK government, CGF focuses on startups that are developing innovative solutions to reduce carbon emissions across critical sectors like power, energy, transport, buildings, and agriculture. The fund’s primary mission is to drive superior financial returns while accelerating the transition to a low-carbon economy, directly contributing to the UK’s Net Zero targets by 2050. CGF typically makes initial investments ranging from £500k to £3 million, primarily during Seed and Series A rounds, and plays an active role in scaling these companies. The fund’s portfolio reflects its commitment to high-impact climate tech, featuring companies like Sunswap, which has developed a zero-emission transport refrigeration unit that can reduce emissions by up to 93%, and Holiferm, a University of Manchester spinout producing eco-friendly biosurfactants for consumer products. Under the leadership of Managing Partner Beverley Gower-Jones, who has over 30 years of experience in clean tech and energy, CGF leverages deep industry expertise to provide more than just capital. The firm actively supports its portfolio companies in achieving their business goals, thus ensuring their innovations make a significant contribution to reducing global carbon emissions. CGF’s strategy aligns with its investors' goals, particularly those managing large funds like the South Yorkshire Pensions Authority and Aviva Investors, who are committed to integrating climate solutions into their portfolios​.

Cleveland Avenue, founded in 2015 and based in Chicago, Illinois, is a venture capital firm that invests in lifestyle consumer brands and technology companies. The firm is dedicated to accelerating growth for entrepreneurs by providing not only financial resources but also strategic support across various business functions. Cleveland Avenue focuses on several sectors including food and beverage, AgTech, consumer goods, and health and wellness. Their portfolio includes innovative companies like Farmer’s Fridge, a vending machine company providing fresh meals; PreciTaste, an AI-enabled foodservice management platform; and Hero, a producer of zero-carb, zero-sugar foods made from plant-based proteins. The firm's approach goes beyond passive investment. They offer a range of services such as financial expertise, organizational development, marketing, supply chain optimization, and operational guidance to help their portfolio companies succeed. Their state-of-the-art Innovation Facility in Chicago serves as a hub for R&D, consumer research, and product showcases. Key figures at Cleveland Avenue include Don Thompson, the CEO, who leverages his extensive experience in corporate leadership to guide the firm's strategic vision, and Joseph McCoy, the COO and General Counsel, who brings a wealth of experience in legal and business transactions.

Climactic VC is a venture capital firm founded in 2021 by Josh Felser, co-founder of Freestyle Capital, and Raj Kapoor, former Chief Strategy Officer at Lyft. The firm focuses on investing in early-stage climate technology startups that are working on innovative solutions to combat climate change. Climactic VC's mission is to support visionary founders who are addressing some of the planet's most pressing challenges, including sustainability, carbon reduction, and creating a more circular economy. The firm's inaugural fund, launched with $65 million, is dedicated to accelerating the growth of software-first climate tech startups. Climactic VC places a strong emphasis on backing companies that can scale rapidly and have the potential to make significant environmental impacts. The firm operates out of New York City and San Francisco, California, reflecting its bi-coastal approach to finding and nurturing top-tier climate tech innovators. Climactic VC is particularly interested in sectors such as energy, mobility, and enterprise solutions that can drive systemic change in how industries operate and how resources are managed. The firm seeks to create partnerships that not only deliver strong financial returns but also contribute meaningfully to the global effort to mitigate climate change.

Climate Capital is an early-stage venture capital firm focused on investing in climate tech startups. Founded in 2018 by Sundeep Ahuja, Climate Capital aims to address climate change through strategic investments in innovative technologies that reduce emissions and promote climate adaptation. The firm supports over 350 teams working on various solutions, including clean energy production, carbon emission reduction, and sustainable lifestyle transformations. Climate Capital operates multiple funds and syndicates, such as the Seed, Growth, Bio, and Climate Scout Fund. This platform approach allows the firm to build expertise across specific verticals and leverage efficiencies of scale. The firm provides founders access to a wide network of partners, resources, and LPs to accelerate growth. Their portfolio includes companies like Mosaic, Moxion Power, and Ampaire, showcasing their commitment to diverse climate solutions. Climate Capital is highly networked, with over 2,500 climate investors, founders, operators, and enthusiasts in their community. This extensive network helps founders find talent, customers, strategic partners, and additional investors.